Navigation Links
Tumors with ALK rearrangements can harbor more mutations
Date:4/22/2013

DENVER The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. But in a recent study published in the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology (JTO) researchers have found that tumors with ALK rearrangements can harbor additional mutations.

Researchers looked at 25 cases of pulmonary adenocarcinoma surgically treated at Mayo Clinic between 1999 and 2007 with ALK gene rearrangement, confirmed by break-apart fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC). Using the DNA extracted from formalin-fixed paraffin-embedded tumor samples, a MassArray-based Lung Cancer Mutations Screening Panel was performed to test for 179 individual mutations in 10 genes, with positive results confirmed by sequencing.

They found additional mutations in 5 of 25 (20 percent) of ALK positive cases. Four of these were point mutation in the MET gene that are of unknown clinical significance, since they may represent germline polymorphisms. However, one case had an EGFR mutation, further supporting that EGFR mutations can be present in ALK rearranged tumors, although it is rare.

"Much is yet to be learned about treatment of patients with both ALK rearrangement and EGFR mutation," the authors report. "Although some of these patients have had a good response to the EGFR inhibitors erlotinib and gefitinib, one patient reportedly showed resistance to erlotinib. Further research is needed to determine if patients with coexisting EGFR mutation and ALK gene rearrangement may have altered response to EGFR or ALK inhibitors. This will be important to determine whether these drugs should be used in a synchronous or sequential fashion to achieve maximum benefit."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Wayne State researchers seek calcium channels to target cancer tumors
2. Hundreds of alterations and potential drug targets to starve tumors identified
3. Hundreds of alterations and potential drug targets to starve cancer tumors identified
4. Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize
5. Virus-like particles provide vital clues about brain tumors
6. Freezing Treatment May Help Destroy Lung Tumors: Study
7. Electrical pulse treatment pokes holes in hard-to-treat tumors
8. AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
9. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
10. Different drug combinations work best for prevention versus treatment of colorectal tumors
11. Engineered T cells kill tumors but spare normal tissue in an animal model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... on smaller and sometimes harder to reach ones, according to the results of ... International Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Sideline Products ... the company met national TV host Tom Seay and his production crew. Tom ... favorite among equestrians around the world. Saddle Sidekicks will be featured on April ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the internet, IdrisArkette.com ... checklist. Over a period of just 24 months, thousands of individuals interested in a ... called T.A.D. , “The internet is not getting quieter. In fact it’s becoming noisier ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ANGLESTRONG ... Kurt Angle, is now available on the App Store and Google ... mobile apps for the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. ...
(Date:2/22/2017)... HEIGHTS, MICHIGAN (PRWEB) , ... February 22, 2017 ... ... and analysis of issues related to spine practices, is featuring Michigan neurosurgeon Jay ... is known as one of a small number of neurosurgeons in Michigan performing ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)...  Bioness, Inc., the leading provider of cutting edge, ... of successful StimRouter Neuromodulation System implantations in ... Netherlands ), South Victoria ... and Kliniek Park Leopold Chirec ( Brussels, Belgium ... to further support clinicians across the continent who are ...
(Date:2/22/2017)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical ... the field of urology, today announced the expansion of ... managers from 35 currently, a 20% increase in the ... expansion is being driven by the increasing growth of ... increasing acceptance of Natesto,s unique product profile and clinical ...
(Date:2/22/2017)... According to a new market research report "Process Analytical Technology Market ... Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & CMO) - ... to reach USD 3.30 Billion by 2021 from USD 1.77 Billion in ... Continue Reading ... ...
Breaking Medicine Technology: